http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jan 2025 16:07:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jan+10/24194701.html si-local-file:///var/storage/secattach/20250110/24194701.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jan+10/24194701.html Fri, 10 Jan 2025 16:07:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jan+10/24194701.html si-local-file:///var/storage/secattach/20250110/24194701.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jan+10/24194701.html Fri, 10 Jan 2025 16:07:00 -0500 ALRN O.06768047 http://www.streetinsider.com/Corporate+News/Aileron+Therapeutics+%28ALRN%29+Announces+Rebranding+to+Rein+Therapeutics+%28RNTX%29/24193485.html <p> Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org">Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to <span>Rein Therapeutics, Inc.</span> The new name, logo, website, and branding elements reflect the Company's mission to develop first-in-class treatments to rein in diseases. The Company's common stock will begin trading under the Nasdaq ticker symbol "RNTX" effective <chron>January 13, 2025</chron>. The CUSIP number for the Company's common stock is not affected by http://www.streetinsider.com/Corporate+News/Aileron+Therapeutics+%28ALRN%29+Announces+Rebranding+to+Rein+Therapeutics+%28RNTX%29/24193485.html Fri, 10 Jan 2025 11:30:40 -0500 ALRN RNTX http://www.streetinsider.com/Corporate+News/Aileron+Therapeutics+%28ALRN%29+Announces+Rebranding+to+Rein+Therapeutics+%28RNTX%29/24193485.html <p> Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org">Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its name to <span>Rein Therapeutics, Inc.</span> The new name, logo, website, and branding elements reflect the Company's mission to develop first-in-class treatments to rein in diseases. The Company's common stock will begin trading under the Nasdaq ticker symbol "RNTX" effective <chron>January 13, 2025</chron>. The CUSIP number for the Company's common stock is not affected by http://www.streetinsider.com/Corporate+News/Aileron+Therapeutics+%28ALRN%29+Announces+Rebranding+to+Rein+Therapeutics+%28RNTX%29/24193485.html Fri, 10 Jan 2025 11:30:40 -0500 ALRN RNTX http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/Press+Releases/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html <div class="xn-content"> <p class="prntac"><i>Rebrand to Rein Therapeutics is representative of the Company's sole focus in developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets</i></p> <p class="prntac"><i>Company shares to begin trading on Nasdaq under the trading symbol "RNTX" effective <chron>January 13, 2025</chron></i></p> <p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Jan. 10, 2025</chron></span> /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as <span value="NASDAQ-NMS:ALRN" idsrc="xmltag.org" >Aileron Therapeutics, Inc.</span> ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has changed its http://www.streetinsider.com/PRNewswire/Aileron+Therapeutics+Announces+Rebranding+to+Rein+Therapeutics/24193476.html Fri, 10 Jan 2025 11:30:00 -0500 A.06822034 ALRN O.06768047 O.20026344 RNTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+05++Filed+by%3A+WINDSOR+JAMES+BRIAN/24082413.html si-local-file:///var/storage/secattach/20241209/24082413.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+05++Filed+by%3A+WINDSOR+JAMES+BRIAN/24082413.html Mon, 09 Dec 2024 16:09:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+05++Filed+by%3A+WINDSOR+JAMES+BRIAN/24082413.html si-local-file:///var/storage/secattach/20241209/24082413.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+05++Filed+by%3A+WINDSOR+JAMES+BRIAN/24082413.html Mon, 09 Dec 2024 16:09:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Aivado+Manuel/24077582.html si-local-file:///var/storage/secattach/20241206/24077582.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Aivado+Manuel/24077582.html Fri, 06 Dec 2024 16:41:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Aivado+Manuel/24077582.html si-local-file:///var/storage/secattach/20241206/24077582.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Aivado+Manuel/24077582.html Fri, 06 Dec 2024 16:41:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Ambros+Reinhard+J./24077557.html si-local-file:///var/storage/secattach/20241206/24077557.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Ambros+Reinhard+J./24077557.html Fri, 06 Dec 2024 16:38:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Ambros+Reinhard+J./24077557.html si-local-file:///var/storage/secattach/20241206/24077557.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Ambros+Reinhard+J./24077557.html Fri, 06 Dec 2024 16:38:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+VON+RICKENBACH+JOSEF+H/24077528.html si-local-file:///var/storage/secattach/20241206/24077528.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+VON+RICKENBACH+JOSEF+H/24077528.html Fri, 06 Dec 2024 16:35:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+VON+RICKENBACH+JOSEF+H/24077528.html si-local-file:///var/storage/secattach/20241206/24077528.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+VON+RICKENBACH+JOSEF+H/24077528.html Fri, 06 Dec 2024 16:35:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Fairey+William/24077529.html si-local-file:///var/storage/secattach/20241206/24077529.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Fairey+William/24077529.html Fri, 06 Dec 2024 16:35:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Fairey+William/24077529.html si-local-file:///var/storage/secattach/20241206/24077529.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Fairey+William/24077529.html Fri, 06 Dec 2024 16:35:00 -0500 ALRN O.06768047 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Musso+Alan+A/24077464.html si-local-file:///var/storage/secattach/20241206/24077464.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Aileron+Therapeutics%2C+++++For%3A+Dec+02++Filed+by%3A+Musso+Alan+A/24077464.html Fri, 06 Dec 2024 16:33:00 -0500 ALRN O.06768047